Ward Capoen
Direttore/Membro del Consiglio presso Augustine Therapeutics NV
Profilo
Ward Capoen is currently a Director at Augustine Therapeutics NV and a Principal at V-Bio Ventures BV.
He previously worked as a Senior Analyst at Candriam Belgium SA from 2013 to 2014.
Posizioni attive di Ward Capoen
Società | Posizione | Inizio |
---|---|---|
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Investitore di Private Equity | 01/01/2019 |
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Ward Capoen
Società | Posizione | Fine |
---|---|---|
Candriam Belgium SA
Candriam Belgium SA Investment ManagersFinance Candriam Belgium SA (Candriam) is the Belgian asset management subsidiary of Candriam Luxembourg SCA, ultimately held by New York Life Insurance Co. in the US. Founded in 1998, the firm was formerly known as Dexia Asset Management Belgium SA, the asset management division of Dexia SA (XB: DEXB). In 2014, New York Life Investments acquired Dexia Asset Management and the firm changed their name to Candriam, which is an acronym of their core values: “Conviction and Responsibility in Asset Management”. Headquartered in Brussels, Candriam provides discretionary and non-discretionary investment advisory services to US registered funds, a limited number of US natural persons, and to institutions. | Analyst-Equity | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Candriam Belgium SA
Candriam Belgium SA Investment ManagersFinance Candriam Belgium SA (Candriam) is the Belgian asset management subsidiary of Candriam Luxembourg SCA, ultimately held by New York Life Insurance Co. in the US. Founded in 1998, the firm was formerly known as Dexia Asset Management Belgium SA, the asset management division of Dexia SA (XB: DEXB). In 2014, New York Life Investments acquired Dexia Asset Management and the firm changed their name to Candriam, which is an acronym of their core values: “Conviction and Responsibility in Asset Management”. Headquartered in Brussels, Candriam provides discretionary and non-discretionary investment advisory services to US registered funds, a limited number of US natural persons, and to institutions. | Finance |
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Finance |
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
- Borsa valori
- Insiders
- Ward Capoen